Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

Also called NCT05226897

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Yooyoung Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT05226897
Other papers using this trial's data
  • A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin Diabetes, obesity & metabolism, 2024-06 DOI, PubMed 38425186

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05226897. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-12 (actual); primary completion 2022-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Intervention (Drug)
YYC405-T
Intervention (Drug)
Metformin≥1000mg
Intervention (Drug)
Dapagliflozin 10mg
Intervention (Drug)
YYC405-T placebo
Lead sponsor
Yooyoung Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05226897
Content hash
7413ea6cb85300e5af9f2b609ac3b054676973cbc112265a99a5ed516ff224fc